Literature DB >> 1722364

Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus.

M Solimena1, P De Camilli.   

Abstract

Stiff-Man syndrome (SMS) is a disorder of the CNS, characterized by rigidity of the body musculature, which has been hypothesized to result from an impairment of GABAergic neurotransmission. GABA is the main inhibitory neurotransmitter of the brain. It is also a putative signal molecule in the pancreas, where it is produced by beta cells (insulin-secreting cells)--the autoimmune target in insulin-dependent diabetes mellitus (IDDM). Autoantibodies to the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD) have been found in SMS and in IDDM. This review summarizes evidence suggesting that SMS may be an autoimmune disease and discusses the possible significance of the autoimmune response to GAD in SMS and IDDM.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1722364     DOI： 10.1016/0166-2236(91)90044-u

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN： 0166-2236            Impact factor:   13.837


  35 in total

Review 1.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

2.  Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Authors:  Arno Hänninen; Merja Soilu-Hänninen; Christiane S Hampe; Angie Deptula; Kelly Geubtner; Jorma Ilonen; Mikael Knip; Helena Reijonen
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

3.  Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies.

Authors:  Esther Ganelin-Cohen; Dalit Modan-Moses; Rina Hemi; Hannah Kanety; Bruria Ben-Zeev; Christiane S Hampe
Journal:  Pediatr Diabetes       Date:  2015-12-29       Impact factor: 4.866

4.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

5.  Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.

Authors:  B Ziegler; M Schlosser; F Lühder; M Strebelow; P Augstein; W Northemann; A C Powers; M Ziegler
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

6.  Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab.

Authors:  A Qureshi; M Hennessy
Journal:  J Neurol       Date:  2011-06-07       Impact factor: 4.849

7.  Anti-Glutamic Acid Decarboxylase Encephalitis Presenting With Choreo-Dystonic Movements and Coexisting Electrographic Seizures.

Authors:  Linda Azevedo Kauppila; Miguel Coelho; Ana Catarina Franco; Tiago Teodoro; Ana Rita Peralta; Carla Bentes; Filipa Falcão; Luísa Albuquerque
Journal:  Mov Disord Clin Pract       Date:  2019-06-25

8.  Stiff man syndrome: neurophysiological findings in eight patients.

Authors:  H M Meinck; K Ricker; P J Hülser; M Solimena
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

9.  Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease.

Authors:  L Geng; M Solimena; R A Flavell; R S Sherwin; A C Hayday
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Direct evidence for limited clonality of antibodies to glutamic acid decarboxylase (GAD) in stiff man syndrome using baculovirus expressed GAD.

Authors:  A P Johnstone; S S Nussey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.